欧盟HMA药品数据库(European Union HMA Authorisation of Medicines DataBase)
MR编号PT/H/2388/002
药品名称Salmeterol/Fluticasone Genetic 25 microgram/125 microgram pressurized inhalation, suspension
活性成分
    • fluticasone propionate 125.0 µg
    • salmeterol xinafoate 25.0 µg
剂型Pressurised inhalation, suspension
上市许可持有人GENETIC SPA VIA G DELLA MONICA 26 CASTEL SAN GIORGIO SA I-84083 ITALY
参考成员国 - 产品名称Portugal (PT)
互认成员国 - 产品名称
    • United Kingdom (Northern Ireland) (XI)
      Salmeterol/Fluticasone Genetic 25 microgram/125 microgram pressurized inhalation, suspension
    • Germany (DE)
      Salmeterol/Fluticasone Genetic 25 microgram/125 microgram per metered dose pressurized inhalation, suspension
    • France (FR)
    • Italy (IT)
    • Greece (GR)
    • Bulgaria (BG)
      Salmeterol/fluticasone Genetic
    • Czechia (CZ)
      Salmeterol/Fluticasone Genetic 25 microgram / 125 microgram per metered dose pressurized inhalation, suspension
    • Romania (RO)
    • Slovakia (SK)
    • Slovenia (SI)
许可日期2019/02/20
最近更新日期2024/03/04
药物ATC编码
    • R03AK06 salmeterol and fluticasone
申请类型
  • TypeLevel1:[not specified]
  • TypeLevel2:[not specified]
  • TypeLevel3:[not specified]
  • TypeLevel4:[not specified]
  • TypeLevel5:[not specified]
附件文件下载
市场状态Positive
©2006-2024 Drugfuture->European Union HMA Authorisation of Medicines DataBase